Results 31 to 40 of about 117,965 (261)

The Future of Anticoagulant Therapy [PDF]

Cardiovascular Therapeutics, 2011
Major advances in the development of oral anticoagulants haveresulted in considerable progress towards the goal of safe and ef-fective oral anticoagulants that do not require frequent monitor-ing or dose adjustment, and have minimal food/drug interactionsas highlighted recently in several reports [1–7] and summarized inrecent reviews in Cardiovascular ...
openaire   +2 more sources

Therapeutic Apheresis for Intravenous Methylprednisolone‐Refractory Neuromyelitis Optica Spectrum Disorder: Clinical and Radiological Outcomes in a Single‐Center Case Series

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing autoimmune disease of the central nervous system. High‐dose intravenous methylprednisolone (IVMP) is the standard first‐line therapy for acute attacks, although some patients remain refractory.
Wataru Horiguchi, Daisuke Katagiri, Takeyuki Watadani, Shunichi Matsuda, Hiroshi Kaneko, Noritoshi Arai   +5 more
wiley   +1 more source

How to define the relative contraindications to oral anticoagulant therapy

Monaldi Archives for Chest Disease, 2017
There is currently a lack of consensus on which anticoagulant therapy contraindications should be considered “absolute” and which should be considered “relative”. Guidelines do not clearly identify absolute and relative contraindications to anticoagulant
Roberto F.E. Pedretti
doaj   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Anticoagulation therapy for intra-abdominal hypertension in patients with acute pancreatitis

BMC Gastroenterology
Background Intra-abdominal hypertension (IAH) is a common complication in patients with acute pancreatitis (AP) and can lead to multiple organ failure. The efficacy of anticoagulant therapy for IAH in patients with acute pancreatitis is unclear.
Yan Ge, Li Ma, Wenwu Sun, Bing Zhao, Ying Chen, Zhitao Yang, Erzhen Chen, Weisong Jiang, Enqiang Mao, Tongtian Ni   +9 more
doaj   +1 more source

Proteasomal degradation of intracellularly expressed Amblyomin‐X limits suicide gene therapy potential in melanoma cells

FEBS Open Bio, EarlyView.
This study explores the feasibility of expressing the antitumoral protein Amblyomin‐X through a suicide gene therapy approach and investigates its intracellular fate after gene delivery. Although the gene is efficiently expressed, melanoma cells rapidly degrade the Amblyomin‐X protein via proteasome activity.
Victor Dal Posolo Cinel, Carlos DeOcesano Pereira, Aline Ramos Maia Lobba, Melissa Regina Fessel, Ana Marisa Chudzinski‐Tavassi   +4 more
wiley   +1 more source

SELECTING AN OPTIMAL LONG-TERM ANTICOAGULANT THERAPY FOR A PATIENT WITH ATRIAL FIBRILLATION AND RECURRENT MINOR HEMORRHAGE. CLINICAL FOLLOW-UP

Атеротромбоз, 2017
For patients with atrial fibrillation, long-term oral anticoagulant therapy reduces the risk of ischemic stroke and systemic embolism, while increasing the risk of hemorrhagic complications.
E. S. Kropacheva, E. P. Panchenko
doaj   +1 more source

D-dimer trends predict recurrent stroke in patients with cancer-related hypercoagulability

Cerebrovascular Diseases Extra, 2023
Introduction: In patients with cancer-associated hypercoagulability (CAH)-related stroke, D-dimer trends after anticoagulant therapy may offer a biomarker of treatment efficacy.
Jun Fujinami, Yoshinari Nagakane, Kei Fujikawa, Shohei Murata, Keiko Maezono, Tomoyuki Ohara, Toshiki Mizuno   +6 more
doaj   +1 more source

Spinal Cord Infarction Versus Idiopathic Transverse Myelitis: Clinical, Radiological, and Functional Insights From a Retrospective Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Spinal cord infarction (SCI) is a rare but devastating myelopathy, characterized by a high disability rate and an unfavorable prognosis. It has often been underdiagnosed and misdiagnosed as idiopathic transverse myelitis (ITM). This study aimed to describe the clinical features, radiological biomarkers, treatments, and functional ...
Zeqiang Ji, Jianlong Zhang, Yiming Shi, Shiyu Shan, Yang Du, Guangshuo Li, Ying Jin, Yani Zhang, Chuanying Wang, Yijun Lin, Yuhao Guo, Decai Tian, Xingquan Zhao, Tian Song   +13 more
wiley   +1 more source

Protocol for a modelling study to assess the clinical and cost-effectiveness of indefinite anticoagulant therapy for first unprovoked venous thromboembolism

BMJ Open, 2023
Introduction Deciding whether to stop or extend anticoagulant therapy indefinitely after completing at least 3 months of initial treatment for a first unprovoked venous thromboembolism (VTE) remains a challenge for clinicians, patients and policy makers.
Marc Rodger, Grégoire Le Gal, Kednapa Thavorn, Faizan Khan, Tobias Tritschler, Dean Fergusson, Doug Coyle, Sasha van Katwyk   +7 more
doaj   +1 more source